DEPRIZINE

DEPRIZINE- ranitidine hydrochloride
California Pharmaceuticals, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Instructions for Preparation Page 1 Page 2

NDC 70332-104-01

For Prescription Compunding Only

Rx only

RapidPaq™ DEPRIZINE™

Ranitidine hydrochloride 25.0mg/mL [equivalent to 22.4 mg/mL rantidine]

Pineapple/Orange oral suspension — kit

RapidPaq™ kits provide a convenient approach to rapidly prepare prescription medications, as all components are pre-measured. This kit is manufactured according to US FDA current Good Manufacturing Practice (cGMP).

Description:

This kit contains active and inactive materials to prepare 250mL of a ranitidine hydochloride Pineapple/Orange oral suspension containing 25.0 mg/mL ranitidine Hydrochloride [equivalent to 22.4 mg/mL ranitidine]. This kit may only be used for prescriptioncompounding by an appropriate licensed medical professional, in response to a physician’s prescription, to create a medication tailored to the specialized needs of an individual patient.

Contents:

— 6.4 ranitidine hydrochloride USP [equivalent to 5.7 g ranitidine]

— 250mL Pineapple/Orange oral suspension vehicle (purified water, glycerin, xylitol, monoammoniumium glycyrrhizinate, pineapple flavor,

orange flavor, potassium sorbate, xanthan gum, sodium benzoate, citric acid, sodium

citrate)

— Press-in bottle adaptor

— Oral dispenser

— Instructions

Pharmacist Instructions for Preparation

1 Remove and Inspect the Contents of the Kit

Ensure that the safety seals are present and intact on the ranitidine hydrochloride and pineapple/orange oral suspension vehicle bottles. If the seals are not intact, do not use the kit.

2 Prepare for Compounding

Wear gloves and eye protection during combining operations. Remove the seal from the Pineapple/Orange oral suspension bottle. Break the perforated seal and remove the cap from the ranitidine hydrochloride bottle.

3 Transfer Ranitidine Hydrochloride to the Pineapple/Orange Suspension Bottle

Uncap the Pineapple/Orange suspension bottle. Pour a small amount of Pineapple/Orange suspension liquid (approximately one-third to one-half the volume of the ranitidine hydrochloride bottle) into the ranitidine hydrochloride bottle. Cap the ranitidine hydrochloride bottle and shake well several times to dissolve the ranitidine hydrochloride powder. Empty the contents into the Pineapple/Orange suspension bottle. Cap and mix the suspension bottle. Repeat this step a minimum of 3 times. Visually ensure that all of the renitidine hydrochloride has been dissolved and transferred to the suspension bottle.

4 Completing the Compounding Process

Insert the press-in bottle adaptor into the Pineapple/Orange suspension bottle that now contains the renitidine hydrochloride. Recap the Pineapple/Orange suspension bottle. Mix well by inverting repestedly several times. Visually ensure that all contents are dissolved.

5 Re-label the Resulting Final Suspension

Label the resulting final suspension as required for prescription products. Ensure that the original Pineapple/Orange oral suspension vehicle label is removed or obscured, since the original label is no longer accurate once the resulting final suspension is completed. The ontents of the bottle need to be shaken well before taken as directed by the medical professional.

Store the unused kit at room temperature of 15-30°C (59-86°F). once prepared, store the mixed suspension between 2-8°C (36-46°F). The resulting final suspension is stable for up to eight weeks, based upon real-time and accelerated stability studies.

An oral dispenser is provided in the kit and may be used to facilitate delivery of the suspension.

U.S. Patents Pending

Repackaged and Distributed by:

California Pharmaceuticals LLC

768 Calle Plano

Camrillo, CA 93012

California

PHARMACEUTICALS LLC

CS43-A1 rev 3

Deprizine Instructions1
(click image for full-size original)
Deprizine Instructions2
(click image for full-size original)

Ranitidine Hydrochloride Product Label

Do not use if safety seal is broken

Ranitidine Hydrochloride

1, 1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2furanyl]-methyl]thio]ehtyl]-N-methyl-2-nitro, monohydrochloride

CAS # 66357-59-3

Net contents: 6.4 g

Repackaged by:

California Pharmaceuticals, LLC

Camarillo, CA 93012

California

PHARMACEUTICALS

CS130-A1 rev 1

Ranitidine HCL label
(click image for full-size original)

Oral Suspension Label

Do not use if safety seal is broken

Deprizine Pineapple/Orange Oral Suspension Vehicle

Sugar, dye, and paraben free

Ingredients: purified water, glycerin, xylitol, monoammoniumium glycyrrhizinate, pineapple flavor, orange flavor, potassium sorbate, xanthan gum, sodium benzoate, citric acid, sodium citrate

Net contents: 250 mL (8.4 fl oz)

Manufactured for:

California Pharmaceuticals LLC

Camarillo, Ca 3012

California

PHARMACEUTICALS LLC

CS36-A-1 rev 2

Suspension Label
(click image for full-size original)

Deprizine Kit Label

NDC 70332-104-01

Rx only

RapidPaq™ Pineapple/Orange Oral Suspension Kit

DEPRIZINE™

(ranitidine hydrochloride 25.0 mg/mL [equivalent to 22.4 mg/mL rantidine],

in a Pineapple/Orange oral suspension kit) Histamine-2 blocker

Description:

This kit contains active and inactive materials to prepare 250mL of a ranitidine hydochloride Pineapple/Orange oral suspension containing 25.0 mg/mL ranitidine hydrochloride [equivalent to 22.4 mg/mL ranitidine]. This kit may only be used for prescriptioncompounding by an appropriate licensed medical professional, in response to a physician’s prescription, to create a medication tailored to the specialized needs of an individual patient.

Active Ingredients:

- 6.4 ranitidine hydrochloride USP [equivalent to 5.7 g ranitidine]

Inactive Ingredients:

- 250mL Pineapple/Orange oral suspension vehicle (purified water, glycerin, xylitol, monoammoniumium glycyrrhizinate, pineapple flavor,

orange flavor, potassium sorbate, xanthan gum, sodium benzoate, citric acid, sodium

citrate)

- Press-in bottle adaptor

- Oral dispenser

- Instructions

U. S. Patents Pending

Do not use if safety seal is broken

Store kit at room temperature,

15-30°C (59-86°F).

California

PHARMACEUTICALS LLC


Repackaged and Distributed by:

California Pharmaceuticals, LLC

768 Calle Plano

Camarillo, Ca 93012

CS129-A1 rev 2

Deprizine Kit Label
(click image for full-size original)
DEPRIZINE
ranitidine hydrochloride kit
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:70332-104
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:70332-104-01 1 KIT in 1 KIT None
Quantity of Parts
Part # Package Quantity Total Product Quantity
Part 1 1 BOTTLE 6.4 g
Part 2 1 BOTTLE 250 mL
Part 1 of 2
RANITIDINE HYDROCHLORIDE
ranitidine hydrochloride powder, for suspension
Product Information
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
RANITIDINE HYDROCHLORIDE (RANITIDINE) RANITIDINE 6.4 g in 6.4 g
Packaging
# Item Code Package Description Multilevel Packaging
1 6.4 g in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 01/01/2016
Part 2 of 2
ORAL VEHICLE
oral vehicle suspension
Product Information
Route of Administration ORAL DEA Schedule
Inactive Ingredients
Ingredient Name Strength
WATER
GLYCERIN
XYLITOL
AMMONIUM GLYCYRRHIZATE
POTASSIUM SORBATE
XANTHAN GUM
SODIUM BENZOATE
SODIUM CITRATE
CITRIC ACID MONOHYDRATE
Product Characteristics
Color Score
Shape Size
Flavor PINEAPPLE (PINEAPPLE;ORANGE) Imprint Code
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 250 mL in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 01/01/2016
Labeler — California Pharmaceuticals, LLC (021420944)
Registrant — California Pharmaceuticals, LLC (021420944)
Establishment
Name Address ID/FEI Operations
California Pharmaceuticals, LLC 021420944 manufacture (70332-104), repack (70332-104)

Revised: 01/2018 California Pharmaceuticals, LLC

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.